Full Press Release Details
Media Advisory - Oncolytics Biotech
Inc. Announces Participation in Upcoming Conferences
CALGARY, Feb. 8, 2016 /CNW/ - Dr. Brad
Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC) (OTCQX: ONCYF) (FRA: ONY), will present at the 18th
Annual BIO CEO & Investor Conference in a session on Tuesday, February 9th, 2016 at 10:30 a.m. ET. The
conference takes place on February 8th and 9th at the Waldorf Astoria in New York, NY.
A live audio link to the webcast session will
be available at: http://www.veracast.com/webcasts/bio/ceoinvestor2016/46211270812.cfm.
Dr. Thompson is also participating in the Life
Sciences Panel and presenting at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference to be held at the
Convene Conference Center, 730 Third Avenue in New York, NY on Wednesday, February 10, 2016 at 10:00 a.m. ET and 1:45 p.m. ET,
A live audio link to the webcast presentation
session will be available at: http://wsw.com/webcast/sourcecap1/oncy.
Links to the presentations will also be available
on the company's website at: http://www.oncolyticsbiotech.com/investor-centre/presentations/. It is recommended that listeners
log on 10 minutes in advance of a live presentation to register and download any necessary software. Links to the audio replays
will be accessible following the presentations on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of later-stage, randomized human trials in various indications using REOLYSIN ,
its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.
The session and webcast times are subject
to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown
risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance
or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking
statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success
and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals
and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake
to update these forward-looking statements, except as required by applicable laws.
SOURCE Oncolytics Biotech Inc.
For further information: NATIONAL Equicom, Nick Hurst, 800
6th Ave. SW, Suite 1600, Calgary, Alberta T2P 3G3, Tel: 403.218.2835, Fax: 403.218.2830, nhurst@national.ca; NATIONAL Equicom,
Michael Moore, San Diego, CA, Tel: 858.886.7813, mmoore@national.ca; Dian Griesel, Inc., Susan Forman, 335 West 38th Street, 3rd
Floor, New York, NY 10018, Tel: 212.825.3210, Fax: 212.825.3229, sforman@dgicomm.com
CO: Oncolytics Biotech Inc.
CNW 17:20e 08-FEB-16